NASDAQ
06.02.26 | 22:00
2,390 US-Dollar
+8,14 % +0,180
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 15.12.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals GAAP EPS of -$0.37 | 3 | Seeking Alpha | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.10.25 | Zentalis to present azenosertib data at cancer therapeutics conference | 5 | Investing.com | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 01.10.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 103 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.09.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 162 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.08.25 | Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary | 4 | GlobeNewswire (USA) | ||
| 26.08.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.07.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 184 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.06.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 137 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.05.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 210 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.04.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 208 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.03.25 | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 231 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
| 03.03.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 189 | GlobeNewswire (Europe) | SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,411 | -3,52 % | News Alarm! Super-Stratege wird Vorstand bei NurExone!! | ||
| IMMUNITYBIO | 5,118 | +0,08 % | ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy | ||
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| ALDEYRA | 4,700 | +0,38 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,114 | -1,45 % | Iovance Biotherapeutics, Inc.: Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma | SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal... ► Artikel lesen | |
| GUARDANT HEALTH | 84,70 | -1,63 % | Krebs-Impfstoff: Chance Teil 2: Phase-2-Start für den Brustkrebs-Impfstoff und starke CAR-T-Daten bei Eierstockkrebs.Wird 2026 der Wendepunkt? | ||
| COHERUS ONCOLOGY | 1,747 | -3,29 % | Coherus Biosciences stock gains on JNJ clinical supply agreement | ||
| OCULAR THERAPEUTIX | 7,700 | -0,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| ESPERION | 2,800 | -2,81 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,126 | +0,51 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| MACROGENICS | 1,457 | -4,58 % | MacroGenics, Inc.: MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress | Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platformRealigned... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,180 (+8,14 %) liegt der Kurs bei 2,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.